Recursion Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Recursion Pharmaceuticals generated cash of -$287,780,000, which is less than the previous year. Cash used in financing activities reached the amount of $140,133,000 last year. Net change in cash is therefore -$157,687,000.
Cash Flow
| 2019 | -57.04M | -3.91M | 120.41M |
|---|---|---|---|
| 2020 | -45.39M | -8.74M | 246.13M |
| 2021 | -158.61M | -271.74M | 458.54M |
| 2022 | -83.52M | 193.24M | 154.34M |
| 2023 | -287.78M | -10.22M | 140.13M |
RXRX Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 559.11M | 295.34M | 267.16M | 75.17M | 15.71M |
Operating activities | |||||
Net income | -328.06M | -239.47M | -186.47M | -87.00M | -61.87M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 24.40M | 11.75M | 8.40M | 4.44M | 2.48M |
Stock-based compensation expense | 53.50M | 27.90M | 14.84M | 4.29M | 1.38M |
| Deferred income tax benefit | 53.50M | 27.90M | 14.84M | 4.29M | 1.38M |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | -2K | 114K | -5K | -27K |
Inventories | 0 | 2K | 7.83M | 4.35M | 0 |
Accounts payable | -987K | 1.76M | 1.74M | -185K | -340K |
Cash generated by operating activities | -287.78M | -83.52M | -158.61M | -45.39M | -57.04M |
Investing activities | |||||
Purchases Of Investments | 0 | 0 | -301.13M | 0 | 0 |
Investments In Property Plant And Equipment | -11.95M | -37.35M | -39.79M | -6.73M | -3.91M |
Acquisitions Net | 1.84M | 0 | 231.94M | -2.6M | 0 |
Cash generated by investing activities | -10.22M | 193.24M | -271.74M | -8.74M | -3.91M |
Financing activities | |||||
Common Stock Issued | 128.09M | 143.71M | 462.90M | 239.81M | 119.70M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -766K | -90K | -12.79M | -77K | 705K |
Cash used in financing activities | 140.13M | 154.34M | 458.54M | 246.13M | 120.41M |
Net Change In Cash | -157.68M | 263.76M | 28.18M | 191.99M | 59.45M |
Cash at end of period | 401.42M | 559.11M | 295.34M | 267.16M | 75.17M |
| Data source | Data source | Data source |